Pokeweed antiviral protein (PAP), a 29-kDa protein isolated from Phytolacca americana inhibits translation by catalytically removing a specific adenine residue from the 28S rRNA of eukaryotic ribosomes. PAP has potent antiviral activity against many plant and animal viruses, including human immunodeficiency virus. We describe here development of a positive selection system to isolate PAP mutants with reduced toxicity. In vitro translation in the presence or absence of microsomal membranes shows that PAP is synthesized as a precursor and undergoes at least two different proteolytic processing steps to generate mature PAP.The PAP cDNA was placed under control of the galactoseinducible GAL] promoter and transformed into Saccharomyces cerevisiae. Induction of PAP expression was lethal to yeast.The PAP expression plasmid was mutagenized and plasmids encoding mutant PAP genes were identified by their failure to kill S. cerevisiae. A number of mutant alleles were sequenced. In one mutant, a point mutation at Glu-177 inactivated enzymatic function in vitro, suggesting that this glutamic acid residue is located at or near the catalytic site. Mutants with either point mutations near the N terminus or a nonsense mutation at residue 237 produced protein that was enzymatically active in vitro, suggesting that the toxicity of PAP is not due solely to enzymatic activity. Toxicity of PAP appears to be a multistep process that involves possibly different domains of the protein.Pokeweed antiviral protein (PAP), a ribosome-inactivating protein (RIP) isolated from the leaves or seeds of Phytolacca americana, catalytically removes a specific adenine residue from a highly conserved stem-loop structure in the 28S rRNA of eukaryotic ribosomes (1, 2). This lesion interferes with elongation factor 2 binding and blocks protein synthesis. PAP was discovered when pokeweed extracts were found to inhibit the transmission of tobacco mosaic virus and was subsequently demonstrated to be equally effective against a number of other plant viruses (3). Studies that compare the relative antiviral properties of a number of RIPs showed that all of the RIPs tested had antiviral activity, but none was as effective as PAP (4). PAP has been shown to inhibit infection of both Vero and HeLa cells by herpes simplex virus (5) and to inhibit human immunodeficiency virus 1 (HIV-1) replication in T cells and macrophages infected in vitro at concentrations that do not inhibit cellular protein synthesis (6). A number of recent studies have shown that conjugating PAP with monoclonal antibodies dramatically increases its potency against cells infected with HIV and human cytomegalovirus (7). In addition, PAP has been used as the cytotoxic moiety of immunotoxins against acute lymphoblastic leukemia and PAPcontaining immunotoxins have shown significant antileukemic activity in clinical trials (7).Single-chain RIPs (type I RIPs), like PAP, are poorly characterized at the molecular level compared to the type II RIP, ricin, which consists of an enzymatically active...